Edgewise Therapeutics, Inc. (EWTX) FY2025 10-K Annual Report
Edgewise Therapeutics, Inc. (EWTX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Edgewise Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Discovery and development of precision small molecule therapies targeting severe skeletal and cardiac muscle diseases
- • New emphasis on sevasemten, an oral fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies with recent FDA Fast Track and Orphan Drug designations
- • Strategic focus shift to advancing muscle fiber stabilizing therapies with potential use as standalone or combination treatment, expanding clinical-stage muscular dystrophy and cardiac programs including EDG-7500 and EDG-15400
- • Pipeline growth with multiple clinical-stage assets and new preclinical candidates, including EDG-003 targeting cardiometabolic diseases
- • FDA approvals and setbacks in gene and exon skipping therapies for Duchenne highlight continued unmet need; Edgewise promotes mutation-agnostic, mechanistically novel approach potentially addressing broader patient populations
Management Discussion & Analysis
- • Net loss $167.8M in 2025 vs $133.8M in 2024, operating expenses rose $32.6M to $191.4M driven by R&D and G&A increases
- • R&D expenses $151.4M vs $127.0M (+19%), led by sevasemten $52.5M, EDG-7500 $18.4M, and new EDG-15400 $7.6M clinical program costs
- • General & admin expenses $40.0M vs $31.9M (+25.6%) due to higher personnel and professional fees
- • Cash from financing $196.1M in 2025 including $200M direct offering; cash used in operating activities $143.8M; cash and equivalents $530.1M at year-end
- • Management expects increasing expenses from advancing clinical trials, regulatory activities, and commercial preparation; risks include clinical trial outcomes, regulatory timing, capital needs, and macroeconomic uncertainties
Risk Factors
- • FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization
- • Macroeconomic risk from U.S. banking sector disruptions; Silicon Valley Bank failure may limit capital market access
- • Dependence on third-party manufacturers for sevasemten, EDG-7500, EDG-15400; supply disruptions could delay trials or commercialization
- • Competition risk from faster, safer, or cheaper products by unnamed competitors could reduce market opportunities
- • Financial risk: net loss $167.8M in 2025, accumulated deficit $546.4M; need for additional capital may dilute stockholders or restrict operations
Edgewise Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$168M
▼ -25.4% YoY
ROE
-32.1%
▼ -299bp YoY
Total Assets
$553M
▲ +13.5% YoY
EPS (Diluted)
$-1.63
▼ -12.4% YoY
Operating Cash Flow
-$144M
▼ -31.9% YoY
Source: XBRL data from Edgewise Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Edgewise Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.